Bespoke market and competitive intelligence for digital health companies

Artificial intelligence (AI) and machine learning (ML) are heralded as the most disruptive technologies in healthcare services in the 21st century, with most leading healthcare and biopharma companies collaborating with technology firms to develop the latest tools and software for predictive analytics, intelligent robot-assisted surgery, chronic care management and understanding human language and analysing images and visuals for better disease detection and medical knowledge representation. Increasing incidence of infectious diseases, more government initiatives and rising healthcare expenditure and new product launches are likely to further drive digitalisation of healthcare. For instance, Pfizer has utilised IBM’s Watson AI technology to discover new immune-oncology drugs and targets, Beta Bionics has developed a wearable “bionic” pancreas called iLet that could manage blood sugar levels in real time in patients with type 1 diabetes, Concerto Health AI is using ML to analyse oncology data, and PathAI is using ML to help pathologists make quicker and more accurate diagnoses. Leading digital healthcare companies need to adopt strategies to increase process efficiency, enhance customer offerings and reduce costs, focusing on digitalisation, to remain competitive. Explore how our healthcare experts can provide research support on aspects of digital healthcare including AI and ML technologies, opportunity assessment, pharma licensing and M&A support

BENEFITS AND IMPACT

Our offering